Grow your brand, now and through patent expiry This blog is part of an ongoing series, A Brave New World: Therapeutic Area Deep Dives
However, 7 cross sectional studies examining acute effects of the GLP-1-based therapies 37,38,39,40,41,42,43 found a significant increase in % FMD following GLP-1-based interventions (mean difference in the changes from baseline: 2.58 [1.68, 3.53] %
Over time, these changes can contribute to constipation, bloating, and shifts in digestive function
So [systems] need to take an active participation or they will, I think, lose some patients to other systems or outside entities. The workforce challenges The first task in responding to the impact of GLP drugs is training, organizing and aligning the workforce to accommodate the major disruption coming their way, given the demographics of patients and their weight